Chronic inflammatory mediators enhance prostate cancer development and progression

Dinesh Thapa, Rita Ghosh

Research output: Contribution to journalComment/debatepeer-review

44 Scopus citations


Chronic inflammation is postulated to influence prostate cancer progression. Preclinical studies have claimed that inflammatory mediators are involved in prostate cancer development and therefore suggested these as attractive targets for intervention. However, among the many pro-inflammatory mediators, there is no consensus regarding the identity of the primary one(s). In clinical studies, chronic inflammation has been found in prostate tumor specimens, and tissues resected for treatment of benign prostatic hyperplasia (BPH). Although collective evidence from molecular, experimental and clinical data suggests that inflammation can contribute or promote prostate carcinogenesis, an etiologic link has not yet been established. Moreover, the role of chronic inflammation in the onset of castration resistant and metastatic disease is unclear. Therefore it is important to open a dialog regarding recent findings on how chronic inflammatory mediators contribute to prostate cancer progression, and their usefulness to prevent disease progression. In this commentary, we assess the current literature with respect to chronic inflammation as a potential initiator and promoter of prostate carcinogenesis and discuss the prospects for its potential clinical applications.

Original languageEnglish (US)
Pages (from-to)53-62
Number of pages10
JournalBiochemical Pharmacology
Issue number2
StatePublished - Mar 15 2015


  • Castrate resistance
  • Chemokines
  • Chronic inflammation
  • Cytokines
  • Prostate cancer
  • Prostate microenvironment

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology


Dive into the research topics of 'Chronic inflammatory mediators enhance prostate cancer development and progression'. Together they form a unique fingerprint.

Cite this